Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE versus ZMAX.
ILOSONE vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (ILOSONE) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis by blocking translocation.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
Erythromycin (Ilosone) base or stearate: 250-500 mg orally every 6 hours. Estolate: 250-500 mg orally every 6 hours. Maximum dose 4 g/day.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
1.5-2 hours in adults; prolonged in hepatic impairment (up to 5-6 hours)
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Renal (2-5% unchanged), biliary/fecal (majority, >90% as metabolites and unchanged drug)
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic